Document is current
Any future updates will be listed below
-
Authors
Li, Zhan-Guo
Hu, Jian-Kang
Li, Xiang-Pei
Yang, Yue
Li, Xing-Fu
Xu, Jian-Hua
Zhang, Xiao
Xu, Jian
Bao, Chun-De
He, Dong-Yi
Li, Zhi-Jun
Wang, Guo-Chun
Zuo, Xiao-Xia
Liu, Yi
Xiao, Zheng-Yu
Chen, Jin-Wei
Xin, Xia-Fei
Li, Jing-Yang
Jiang, Lin-Di
Liu, Meng-Ru
Ji, Fei
Li, Chen-Ge
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct02265705 at ClinicalTrials.govDocuments that mention this clinical trial
SAT0218 Efficacy and safety of baricitinib in mtx-ir patients with rheumatoid arthritis: 52 week results from a phase 3 study (RA-BALANCE)
https://doi.org/10.1136/annrheumdis-2018-eular.1983
Safety of baricitinib for the treatment of rheumatoid arthritis over a median of 4.6 and up to 9.3 years of treatment: final results from long-term extension study and integrated database
https://doi.org/10.1136/annrheumdis-2021-221276
Rapid Onset of Efficacy of Baricitinib in Chinese Patients with Moderate to Severe Rheumatoid Arthritis: Results from Study RA-BALANCE
https://doi.org/10.1007/s12325-020-01572-y
-
Funding
Funding for this research was provided by:
Eli Lilly and Company
- License Information
-
More Information
Article History
Received: 19 October 2020
Accepted: 11 November 2020
First Online: 25 November 2020
